Left ventricular hypertrophy (LVH) is a generalized adaptation to altered myocardial load. Hypertension induces significant increases in ventricular IGF-I gene expression that occur coordinately with development of LVH. To test whether IGF-I promotes initiation of LVH, we examined ventricular IGF-I mRNA content in spontaneously hypertensive rats (SHRs) treated with antihypertensive drugs that limit or permit LVH.
Methods
Prehypertensive SHRs were left untreated or treated with enalapril, nifedipine, or hydralazine. Systolic blood pressure (SBP), hypertrophy index (ventricular weight/body weight), and ventricular IGF-I mRNA levels were examined 2, 4, and 6 weeks after beginning therapy in the experimental groups.
Results
Systolic blood pressure reached hypertensive levels after 2 weeks in untreated animals, and was controlled in the treated animals. The hypertrophy index in untreated animals was significantly elevated at 4 weeks. By 6 weeks, the hypertrophy indices of both the enalapril- and nifedipine-treated groups were significantly lower than that of the untreated group. In contrast, the hypertrophy index of the hydralazine-treated animals remained comparable to that of the untreated animals. By 4 weeks, IGF-I mRNA levels in the enalapril- and nifedipine-treated groups were significantly lower than those in the untreated and hydralazine-treated groups.
Conclusions
We conclude that: (1) antihypertensive drugs that reduce LVH blunt ventricular IGF-I mRNA content; and (2) the hemodynamic effects of antihypertensives may be dissociated from their ability to promote or limit a hypertrophic response. The clear association of LVH with ventricular IGF-I mRNA content suggests that IGF-I is an important determinant of ventricular growth. Our data also suggest that angiotensin-converting enzyme inhibitors and calcium channel blockers may reduce LVH by inhibiting cardiac IGF-I gene expression.
CasalePN, DevereuxR, MilnerM, ZulloG, HarshfieldGA, PickeringTG, LaraghJH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med1986;105:173–8.
IzumoS, Nadal-GinardB, MahdaviV.Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA1988;85:339–43.
4.
SchwartzK, de la BastieD, BouveretP, OlivieroP, AlonsoS, BuckinghamM.Skeletal muscle actin mRNAs accumulate in hypertrophied adult rat hearts. Circ Res1986; 59:551–5.
5.
IzumoS, LompreAM, MatsuokaR, KorenG, SchwartzK, Nadal-GinardB, MahdaviV.Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. J Clin Invest1987;79:970–7.
6.
KomuroI, KurabayashiM, TakakuF, YazakiY.Expression of cellular oncogenes in the myocardium during developmental stage and pressure overload hypertrophy of the rat heart. Circ Res1988;62:1075–9.
7.
DonohueTJ, DworkinLD, LangoMN, FliegnerK, LangoRP, BensteinJA, SlaterWR, CataneseVM. Induction of myocardial insulinlike growth factor-I gene expression in left ventricular hypertrophy. Circulation1994;89:799–809.
8.
EngelmannGL, BoehmKD, HaskellJF, KhairallahPA, IlanJ.Insulin-like growth factors and neonatal cardiomyocyte development: ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats. Mol Cell Endocrinol1989;63:1–14.
9.
SenS, TaraziRC, BumpusFM. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res1977;11:427–33.
10.
JespersonLT, NyborgNCB, PedersonOL, MikkelsenEO, MulvanyMJ. Cardiac mass and peripheral vascular structure in hydralazine-treated spontaneously hypertensive rats. Hypertension1985;7:734–41.
11.
TsoporisJ, LeenenFHH. Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension1988;11:376–86.
12.
DunnFG, OigmanW, VenturaHO, MesserliFH, KobrinI, FrohlichED. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol1984;53:105–8.
13.
NakashimaY, FouadFM, TaraziRC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol1984;53:1044–9.
14.
AmodeoC, KobrinI, VenturaHO, MesserliFH, FrohlichED. Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. Circulation1986;73:108–13.
15.
DunnFG, VenturaHO, MesserliFH, KobrinI, FrohlichED. Time course of regression of left ventricular hypertrophy in hypertensive patients treatedwith atenolol. Circulation1987;76:254–8.
16.
SchmiederRE, MesserliFH, GaravagliaGE, NunezBD. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation1987;75:1030–6.
17.
PfefferJM, PfefferMA, FrohlichED. Validity of an indirect tailcuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med1971;78:957–62.
18.
MeltzerSJ, ManeSM, WoodPK, JohnsonL, NeedlemanSW. An improvement of the single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Biotechniques1987;8:148–9.
19.
ChomczynskiP, SacchiN.Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem1987;162:156–9.
20.
MurphyLJ, BellGI, DuckworthML, FriesenHG. Identification, characterization, and regulation of a complementary deoxyribonucleic acid which encodes insulin-like growth factor-I. Endocrinology1987;121:243–8.
21.
LoweWLJr, RobertsCTJr, LaskySR, LeRoithD.Differential expression of alternative 5'-untranslated regions in mRNAs encoding rat insulin-like growth factor-I. Proc Natl Acad Sci USA1987;84:8946–50.
22.
FortP, MartyL, PiechaczykM, El SabroutyS, DaniC, JeanteurP, BlanchardJM. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate dehydrogenase multigenic family. Nuc Acids Res1985;13:1431–42.
23.
FeinbergAP, VogelsteinB.A technique for radiolabelling DNA restriction fragments to high specific activity. Anal Biochem1983;132:6–13.
24.
MacaraIG. Oncogenes and cellular signal transduction. Physiol Rev1989;69:797–820.
25.
WickstromEL, BaconTA, GonzalezA, FreemanDL, LymanGH, WickstromE.Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci USA1988;85:1028–32.
26.
HeikkilaR, SchwabG, WickstromE, LokeS, PluznikDH, WattR, NeckersLM. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from Go to G1. Nature1987;328:445–9.
27.
BiroS, FuY, YuZ, EpsteinSE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA1993;90:654–8.
28.
AraiH, NakaoK, SaitoY, MoriiN, SugawaraA, YamadaT, ItohH, ShionoS, MukoyamaM, OhkuboH, NakanishiS, ImuraH.Augmented expression of atrial natriuretic polypeptide gene in ventricles of SHR and SHR-stroke prone rats. Circ Res1988;62:926–30.
29.
LeeRT, BlochKD, PfefferJM, PfefferMA, NeerEJ, SeidmanCE. ANF gene expression in ventricles of rats with spontaneous biventricular hypertrophy. J Clin Invest1988;81:431–4.
30.
Eppenberger-EberhardtM, FlammeI, KurerV, EppenbergerHM. Reexpression of alpha-smooth muscle actin isoform in cultured adult rat cardiomyocytes. Devel Biol1990;139:269–78.
31.
EidH, LarsonDM, SpringhornJP, AttawiaMA, NayakRC, SmithTW, KellyRA. Role of epicardial mesothelial cells in the modification of phenotype and function of adult rat ventricular myocytes in primary coculture. Circ Res1992;71:40–50.
32.
ClaycombWC. ANF mRNA is developmentally regulated in heart ventricles and actively expressed in cultured ventricular cardiac muscle cells of rat and human. Biochem J1988;255:617–20.
33.
Eppenberger-EberhardtM, MesserliM, EppenbergerHM, ReineckeM.New occurrence of ANF and storage in secretorially active granules in adult rat ventricular cardiomyocytes in long-term culture. J Mol Cell Cardiol1993;25:753–7.
34.
NagAC, ChengM.Biochemical evidence for cellular dedifferentiation in adult rat cardiac muscle cells in culture: expression of myosin isozymes. Biochem Biophys Res Commun1986;137:855–62.
35.
EppenbergerME, HauserI, BaechiT, SchaubMC, BrunnerUT, DechesneCA, EppenbergerHM. Immunocytochemical analysis of the regeneration of myofibrils in long-term cultures of adult cardiomycytes of the rat. Dev Biol1988;130:1–15.
36.
UenoH, PerrymanMB, RobertsR, SchneiderMD. Differentiation of cardiac myocytes after mitogen withdrawal exhibits three sequential states of the ventricular growth response. J Cell Biol1988;107:1911–8.
37.
ParkerTG, PackerSE, SchneiderMD. Peptide growth factors can provoke “fetal” contractile protein gene expression in rat cardiac myocytes. J Clin Invest1990; 85:507–14.
38.
BugaiskyLB, ZakR.Differentiation of adult rat cardiac myocytes in cell culture. Circ Res1989;64:493–500.
39.
VillarealFJ, DillmanWH. Cardiac hypertrophy-induced changes in messenger RNA levels for TGF-beta1, fibronectin and collagen. Am J Physiol1992;262:H1861–6.
40.
KardamiE, FandrichRR. Heparin-binding mitogen(s) in the heart: in search of origin and function. In: KedesL, StockdaleF, eds. Cellular and molecular biology of muscle development. New York: Liss; 1989:315–25.
41.
ItoH, HiroeM, HirataY, TsujinoM, SchichiriM.IGF-I induces cardiac hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circulation1993;87:1715–21.
42.
DonathMY, ZapfJ, Eppenberger-EberhardtM, FroeschER, EppenbergerHM. IGF-I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. Proc Natl Acad Sci USA1994;91:1686–90.
43.
DuerrRL, HuangS, MiraliakbarHR, ClarkR, ChienKR, RossJJr. Insulin-like growth factor-I enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest1995;95:619–27.
44.
DzauVJ. Cardiac renin-angiotensin system: molecular and functional aspects. Am J Med1988;84 (suppl 3A):22–7.
45.
BakerKM, CherninMI, WixsonSK, AcetoJF. Reninangiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol1990;259:H324–32.
46.
GeisterferAAT, PeachMJ, OwensGK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res1988;62:749–56.
47.
BerkBC, VekshteinV, GordonHM, TsudaT.Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension1989; 13:305–14.
48.
SadoshimaJ, XuY, SlayterHS, IzumoS.Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell1993; 75:977–84.
49.
BakerKM, CherninMI, WixsonSK, AcetoJF. Reninangiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol1990;259:H324–32.
50.
BrinkM, DelafontaineP.Angiotensin II stimulates insulin-like growth factor I gene expression in rat heart. Circulation1995;92:162–3.
51.
DelafontaineP, LouH.Angiotensin II regulates IGF-I gene expression in vascular smooth muscle cells. J Biol Chem1993;268:16866–70.
52.
RabinowitzB, ParmleyWW, Har-ZahavY, ElazarE, BlumleinS, NerinskyR, NeufeldHN. Correlation between effects of hydralazine on force and on the adenyl cyclase system of ventricular myocardium in dogs and cats. Cardiovasc Res1986;20:215–20.
53.
TsoporisJ, FieldsN, LeeRMKW, LeenenFHH. Arterial vasodilation and cardiovascular structural changes in normotensive rats. Am J Physiol1991;260:H1944–H52.
54.
LimasC, WestrumB, LimasCJ. Comparative effects of hydralazine and captopril on the cardiovascular changes in spontaneously hypertensive rats. Am J Pathol1984;117:360–71.
55.
LeenenFHH, SmithDL, FarkasRM, ReevesRA, Marquez-JulioA.Vasodilators and regression of cardiac hypertrophy: hydralazine versus prazosin in hypertensive humans. Am J Med1987;82:969–78.
56.
SimpsonP, McGrathA, SavionS.Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res1982;51:787–801.
57.
SadoshimaJ, IzumoS.Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Circ Res1993;73:424–38.
58.
HenrichCJ, SimpsonPC. Differential acute and chronic response of protein kinase C in cultured neonatal rat heart myocytes to alpha-1-adrenergic and phorbol ester stimulation. J Mol Cell Cardiol1988:20:1981–5.
